KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $21.5 million.

  • AbCellera Biologics' Current Deferred Revenue rose 5745.72% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 million, marking a year-over-year increase of 5745.72%. This contributed to the annual value of $19.2 million for FY2024, which is 2921.22% down from last year.
  • As of Q3 2025, AbCellera Biologics' Current Deferred Revenue stood at $21.5 million, which was up 5745.72% from $28.6 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Current Deferred Revenue high stood at $41.1 million for Q4 2022, and its period low was $13.7 million during Q3 2024.
  • Its 5-year average for Current Deferred Revenue is $29.3 million, with a median of $32.0 million in 2022.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 6036.46% in 2024, then surged by 9888.66% in 2025.
  • Quarter analysis of 5 years shows AbCellera Biologics' Current Deferred Revenue stood at $35.0 million in 2021, then grew by 17.66% to $41.1 million in 2022, then tumbled by 33.98% to $27.2 million in 2023, then dropped by 29.21% to $19.2 million in 2024, then grew by 12.05% to $21.5 million in 2025.
  • Its last three reported values are $21.5 million in Q3 2025, $28.6 million for Q2 2025, and $32.5 million during Q1 2025.